Sarepta Therapeutics, Inc. (SRPT)
Automate Your Wheel Strategy on SRPT
With Tiblio's Option Bot, you can configure your own wheel strategy including SRPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRPT
- Rev/Share 24.0801
- Book/Share 13.17
- PB 1.3759
- Debt/Equity 0.947
- CurrentRatio 2.9545
- ROIC -0.0492
- MktCap 1898740440.0
- FreeCF/Share -3.8792
- PFCF -4.8831
- PE -6.6895
- Debt/Assets 0.3579
- DivYield 0
- ROE -0.2031
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | SRPT | Barclays | -- | Equal Weight | -- | $20 | Jan. 28, 2026 |
| Initiation | SRPT | Wedbush | -- | Outperform | -- | $32 | Dec. 9, 2025 |
| Upgrade | SRPT | Mizuho | Neutral | Outperform | -- | $26 | Nov. 5, 2025 |
| Upgrade | SRPT | BMO Capital Markets | Market Perform | Outperform | -- | $50 | Sept. 22, 2025 |
| Upgrade | SRPT | JP Morgan | Underweight | Neutral | -- | $24 | July 29, 2025 |
| Upgrade | SRPT | Oppenheimer | Perform | Outperform | -- | $37 | July 29, 2025 |
| Upgrade | SRPT | Barclays | Underweight | Equal Weight | -- | $22 | July 29, 2025 |
| Initiation | SRPT | Bernstein | -- | Market Perform | -- | $13 | July 29, 2025 |
| Reiterated | SRPT | H.C. Wainwright | -- | Sell | -- | $5 | July 29, 2025 |
| Downgrade | SRPT | Barclays | Equal Weight | Underweight | -- | $10 | July 28, 2025 |
News
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
Published: July 21, 2025 by: Forbes
Sentiment: Negative
Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.
Read More
Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
Read More
Sarepta stock extends decline as company declines FDA call to withdraw drug
Published: July 21, 2025 by: Market Watch
Sentiment: Negative
Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and Drug Administration request to stop selling a drug tied to three deaths.
Read More
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
Read More
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 18, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $SRPT--SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Read More
Sarepta Therapeutics, Inc. (SRPT) Strategic Restructure and ELEVIDYS Label Update Call Transcript
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Company Participants Douglas S. Ingram - President, CEO & Director Ian Estepan - Corporate Participant Louise Rodino-Klapac - Corporate Participant Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Biren N.
Read More
Sarepta shares plunge 30% as future of its gene therapy appears at risk
Published: July 18, 2025 by: CNBC
Sentiment: Negative
Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should stay on the market. Sarepta has reported three patient deaths related to its gene therapies.
Read More
Sarepta shares sink on 3rd patient death amid restructuring statement
Published: July 18, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Sarepta following a patient death.
Read More
Sarepta's Setback Deepens With Another Gene Therapy Fatality
Published: July 18, 2025 by: Benzinga
Sentiment: Negative
Sarepta Therapeutics SRPT shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company's recent efforts to provide clarity on its restructuring and FDA label plans.
Read More
Sarepta shares sink on third gene therapy-linked death
Published: July 18, 2025 by: Proactive Investors
Sentiment: Negative
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares pulled back after Thursday's gains on the announcement of a third patient death linked to the company's experimental gene therapies. The patient, who was participating in a Phase 1 trial for Sarepta's approved AAVrh74-based gene therapy targeting limb-girdle muscular dystrophy, died from acute liver failure.
Read More
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.
Read More
Sarepta shares soar on restructuring, R&D refocus
Published: July 17, 2025 by: Proactive Investors
Sentiment: Positive
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped on a sweeping restructuring plan that includes cutting about 500 jobs, or 36% of its workforce, in a move aimed at reducing annual operating expenses by $400 million by 2026. The biotech company said it will sharpen its focus on high-impact drug development programs, particularly its small interfering RNA (siRNA) platform targeting neurodegenerative and pulmonary diseases such as facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy type 1, and Huntington's disease.
Read More
The Gross Law Firm Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Sarepta Therapeutics: What's Happening With SRPT Stock?
Published: July 17, 2025 by: Forbes
Sentiment: Negative
Sarepta Therapeutics stock (NASDAQ: SRPT) experienced a significant turnaround on Wednesday, with shares rising 33% in after-hours trading following the announcement of an extensive restructuring plan, which involves laying off 500 employees — nearly 40% of its workforce of over 1,300. The company also plans to halt several gene therapy programs, including the majority of its limb-girdle muscular dystrophy initiatives.
Read More
Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box' Warning Are Good News.
Published: July 17, 2025 by: Barrons
Sentiment: Positive
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene therapy Elevidys.
Read More
Sarepta: Finally, A Little Relief For Bulls; I Expect More
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
Sarepta's turnaround is just beginning, with decisive management actions like layoffs boosting confidence and saving $100 million annually. The market had priced in the worst for Elevidys, but the FDA's black box warning was a positive surprise, opening potential future catalysts. Sarepta is not a one-trick pony; upcoming clinical results for SRP-9003 and other pipeline assets add upside optionality.
Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
Read More
Sarepta Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPT
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Read More
Faruqi & Faruqi Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Published: July 15, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" or the …
Read More
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Published: July 13, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , July 13, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v.
Read More
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Published: July 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025.
Read More
About Sarepta Therapeutics, Inc. (SRPT)
- IPO Date 1997-06-04
- Website https://www.sarepta.com
- Industry Biotechnology
- CEO Douglas S. Ingram
- Employees 1372